Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Growth in Short Interest

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 409,800 shares, a growth of 21.1% from the March 31st total of 338,500 shares. Based on an average daily trading volume, of 4,000 shares, the short-interest ratio is presently 102.5 days.

Zealand Pharma A/S Trading Down 0.6 %

ZLDPF stock opened at $86.25 on Tuesday. Zealand Pharma A/S has a one year low of $32.42 and a one year high of $111.44. The firm has a 50-day moving average of $92.94 and a two-hundred day moving average of $67.65. The firm has a market capitalization of $4.44 billion, a PE ratio of -47.39 and a beta of 0.63.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Tuesday, February 27th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). The business had revenue of $3.35 million during the quarter, compared to analysts’ expectations of $1.97 million. Zealand Pharma A/S had a negative net margin of 203.99% and a negative return on equity of 49.78%. On average, equities research analysts anticipate that Zealand Pharma A/S will post -2.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, BTIG Research initiated coverage on Zealand Pharma A/S in a research note on Thursday, March 7th. They issued a “buy” rating on the stock.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.